SCHEMBL4596111

SCHEMBL4596111

CC(C)C(C(=O)O)c1ccc(-c2ccc(C(F)(F)F)cc2)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 9/20 0.61
AKR1C2 P52895 9/20 0.61
PSEN1 P49768 3/20 0.52
PSEN2 P49810 3/20 0.52
APH1B Q8WW43 3/20 0.52
NCSTN Q92542 3/20 0.52
APH1A Q96BI3 3/20 0.52
PSENEN Q9NZ42 3/20 0.52
APP P05067 2/20 0.48
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP3 P08254 1/20 0.44
MMP7 P09237 1/20 0.44
MMP9 P14780 1/20 0.44
MMP13 P45452 1/20 0.44
BACE1 P56817 1/20 0.44
KCNH2 Q12809 2/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
CASR P41180 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11387013 0.85 AKR1C3 (0.50) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL4597658 0.83 AKR1C3 (0.74) AKR1C3AKR1C2PSEN1PSEN2APH1B
Hydrochloric Acid SCHEMBL11157153 0.83 AKR1C3 (0.49) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL4597117 0.82 PSEN1 (0.72) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL4597477 0.81 AKR1C3 (0.56) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL4597558 0.81 AKR1C3 (0.65) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL6477785 0.80 PSEN1 (0.54) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL4597386 0.79 PSEN1 (0.54) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL4597484 0.77 PSEN1 (0.52) AKR1C3AKR1C2PSEN1PSEN2APH1B
SCHEMBL4597051 0.77 AKR1C3 (0.51) AKR1C3AKR1C2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773315-B1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (GB) 2008-01-16 EP claimed
US-20080300261-A1 Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-12-04 US disclosed
EP-1773315-B1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (GB) 2008-01-16 EP disclosed
EP-1773315-A1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE Merck Sharp & Dohme Limited (GB) 2007-04-18 EP disclosed
WO-2006008558-A1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300261-A1 Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease PSEN2, PSEN1, NAT1 AKR1C3 521/4885AKR1C2 476/4885PSEN1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.